Controlled Substances - As enacted, authorizes additional healthcare providers to directly administer buprenorphine mono or buprenorphine without the use of naloxone; adds that prescribing a buprenorphine product to nursing mother or prescribing an injectable mono product does not restrict certain healthcare providers from prescribing a buprenorphine product for the treatment of opioid use disorder without naloxone. - Amends TCA Title 53, Chapter 11.

Official Bill Page

Loading official bill page…

14 actions

Apr 24, 2026 lower

Comp. became Pub. Ch. 753
Mar 30, 2026 lower

Companion House Bill substituted
Mar 27, 2026 lower

Placed on Senate Regular Calendar for 3/30/2026
Mar 18, 2026 lower

Recommended for passage, refer to Senate Calendar Committee
Mar 17, 2026 lower

Action deferred in Senate Health and Welfare Committee to 3/18/2026
Mar 17, 2026 lower

Placed on Senate Health and Welfare Committee calendar for 3/18/2026
Mar 11, 2026 lower

Action deferred in Senate Health and Welfare Committee to 3/18/2026
Mar 11, 2026 lower

Placed on Senate Health and Welfare Committee calendar for 3/17/2026
Mar 4, 2026 lower

Placed on Senate Health and Welfare Committee calendar for 3/11/2026
Feb 18, 2026 lower

Action deferred in Senate Health and Welfare Committee to 3/4/2026
Feb 11, 2026 lower

Placed on Senate Health and Welfare Committee calendar for 2/18/2026
Feb 2, 2026 upper

Passed on Second Consideration, refer to Senate Health and Welfare Committee
Jan 22, 2026 lower

Introduced, Passed on First Consideration
Jan 21, 2026 lower

Filed for introduction